JPM: Lilly, Moderna, insitro CEOs say pandemic forced R&D, marketing and ops changes worth keeping

JPM: Lilly, Moderna, insitro CEOs say pandemic forced R&D, marketing and ops changes worth keeping

Source: 
Fierce Pharma
snippet: 

A prime example of the pandemic's complete overhaul of biopharma's work life is the first-ever virtual format of the J.P. Morgan Healthcare Conference. But there are plenty of others—and biopharma CEOs are saying this week that the industry will adopt some of those changes for good.